Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STREAM-Line: Apixaban for Secondary Prevention of VTE in Cancer Patients with Catheter-Related Upper Extremity DVT
NCT06603870Phase 4Recruiting
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Dec 2024
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of apixaban in venous thromboembolism (VTE), upper extremity deep vein thrombosis (UEDVT), sponsored by Ottawa Hospital Research Institute. Started Dec 2024; status: recruiting.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)upper extremity deep vein thrombosis (UEDVT)
Beyond the preview
Go deeper on NCT06603870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06603870.